Company intelligence / Profile preview
AusperBio
San Mateo, California, United Statesausperbio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
AusperBio’s lead program AHB‑137 has completed a global Phase Ib trial and is in multiple Phase II trials in China. Interim Phase IIa data were presented at the AASLD conference in late 2024. The company reports promising preclinical and early clinical results for its dual-mechanism ASO approach to HBV cure.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Antisense oligonucleotides (ASO)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on AusperBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AusperBio.